SLNO Q2 2024 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$494,000

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-0.57

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$304M

Total Liabilities

$23M

Stockholders' Equity

$281M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$494,000	$0	—
Operating Income	-$23M	-$9M	-169.4%
Net Income	-$22M	-$8M	-157.9%